we could go on for days about this one, but let's just score the highlights, shall we?let's start with this: it appears that genentech has 2 drugs that are equally effective in treating a leading cause of blindness in the elderly. one has a projected cost to patients of us$60, the other us$2,000. guess which one they're not going to make?
there are also new drug labeling regulations coming out this month that will provide legal protection to drug companies that withhold information on risks involved in using their products. (this move is part of an overall campaign by the bush administration since dubya took office to shield companies from lawsuits.)
another possibly-on-purpose failure of the current adminsitration: insufficient oversight of medicare drug programs. and all of this in a time when shrinks have moved to prescribing drugs rather than using talk therapy. soma, anyone?